Atrial Fibrillation Ablation without Interruption of Anticoagulation

Area of Science:

• Cardiology
• Electrophysiology

Background:

• Atrial fibrillation (AF) ablation, specifically pulmonary vein antrum isolation (PVAI), offers a cure for many patients.
• PVAI efficacy is limited by periprocedural risks like thromboembolism and bleeding.
• Optimal anticoagulation management is crucial for mitigating these risks during AF ablation.

Purpose of the Study:

• To evaluate the feasibility and safety of performing PVAI without interrupting oral anticoagulation.
• To compare the risks of stroke and bleeding between continuous warfarin therapy and heparin bridging during AF ablation.

Main Methods:

• Patients undergoing radiofrequency catheter ablation for AF were managed with continuous therapeutic warfarin.
• A comparison group received heparin bridging after warfarin interruption.
• Outcomes assessed included periprocedural stroke, transient ischemic attack, and bleeding events.

Main Results:

• Continuation of therapeutic warfarin during AF ablation significantly reduced the risk of periprocedural stroke/transient ischemic attack.
• This strategy did not increase the risk of hemorrhagic events compared to heparin bridging.
• Heparin bridging was associated with an increased risk of minor bleeding.

Conclusions:

• Continuing therapeutic warfarin during AF ablation is a safe and effective anticoagulation strategy.
• This approach minimizes stroke risk while maintaining an acceptable bleeding profile.
• AF ablation without anticoagulation interruption represents the optimal management strategy.